![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 15, 2020 4:06:28 AM
LOS ANGELES, CA / ACCESSWIRE / September 15, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the :10.5 GenViro! Professional Swift Kit for testing Covid-19 testing, today announced that it has entered into agreement with a major investor for a six month 8% Promissory Note. Principal and interest will be due and payable in six months.
Separately the company has announced that six existing Promissory Notes with the same investor have been extended for an additional four (4) months each. The new Note and the previous Notes are for payment of principal and interest only. No conversion rights are included. The company had previously announced that the GenViro! Swift kit will be available for sale on September 26, 2020 in select International venues.
https://www.accesswire.com/606026/DECN-Enters-into-an-Additional-6-Month-300000-Promissory-Note-With-Major-Current-Investor-to-Further-Assist-Launch-of-Genviro-Swift-Kits-for-the-Detection-of-the-Covid-19-Virus
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM